



## Entresto® (sacubitril/valsartan) – Expanded indication

- On February 16, 2021, [Novartis announced](#) the FDA approval of [Entresto \(sacubitril/valsartan\)](#), to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in *adult patients with chronic heart failure (CHF)*. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
  - LVEF is a variable measure, so use clinical judgment in deciding whom to treat.
  - Entresto was previously approved to reduce the risk of cardiovascular death and hospitalization for HF in patients with *CHF (NYHA Class II-IV) and reduced ejection fraction*.
- Entresto is also approved for the treatment of symptomatic HF with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- Approximately 6 million people in the U.S. are living with CHF. Approximately 3 million have reduced ejection fraction, and of the remaining 3 million, about 2 million have preserved ejection fraction HF with LVEF below normal.
  - Entresto is the first approved therapy for both those with HF with reduced ejection fraction and many with HF with preserved ejection fraction.
- The approval of Entresto for the expanded indication was based on the PARAGON-HF trial, a randomized, double-blind study in 4,796 adult patients with symptomatic HF with left ventricular ejection fraction  $\geq 45\%$ , and structural heart disease. Patients received either Entresto or valsartan. The primary endpoint was the rate of the composite endpoint of total (first and recurrent) HF hospitalizations and cardiovascular death.
  - Entresto had a numerical reduction in the rate of the composite endpoint (rate ratio [RR] 0.87, 95% CI: 0.75, 1.01;  $p = 0.06$ ). The event rate was 12.8 and 14.6 for Entresto and valsartan, respectively.
  - The treatment effect was primarily driven by the reduction in total HF hospitalizations in patients randomized to Entresto (RR 0.85, 95% CI: 0.72, 1.00).
- The recommended starting dose of Entresto for the treatment of adults with HF is 49/51 mg orally twice daily. The dose of Entresto should be doubled after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
  - Refer to the Entresto drug label for pediatric dosing.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.